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Anxiety Symptoms as a Predictor of Head and Neck Cancer Survival
and Potential for Mediation by Cancer Treatment Response
Introduction
Approximately 630,000 people are expected to develop head and neck cancer (HNC) this
year, ranking it the sixth most common cancer worldwide(Parkin, Bray, Ferlay, & Pisani, 2005).
White males are the most at-risk group for developing HNC--almost 3 times more likely than
white females—and tobacco and alcohol use greatly increase that risk(U.S. Cancer Statistics
Working Group, 2018). The impacts of HNC on patients include significant decreases in healthrelated quality of life (HRQOL) paired with invasive surgeries that often result in severe facial
disfigurement. Tumors of the head and neck are rarely diagnosed in their early stages and are
often aggressive in nature, which emphasizes their high mortality. Additionally, many do not
respond well to treatment, causing complications while costing patients valuable time. Therefore,
the typical patient newly diagnosed with HNC can expect his/her tumor(s) to already be at an
advanced stage, a decline in his/her ability to eat and/or communicate, expensive and invasive
multimodal treatment, and facial disfigurement after surgery, if performed. Each of these likely
circumstances contribute to patient feelings of anxiety about what brand of suffering awaits him/
her, which may influence the patient’s attendance to treatment and even the treatment’s outcome.
The Diagnostic and Statistical Manual (DSM-5) defines generalized anxiety to be
excessive worry that is difficult to control and causes significant impairment in social,
occupational, or other important areas of functioning(American Psychiatric Association, 2013).
Research has shown evidence of anxiety in HNC patients at all stages of the disease, but its
association with clinical outcomes remains underrepresented in the literature(Howren,
Christensen, Karnell, & Funk, 2013). For example, one study used a modified distress
thermometer to assess “mask anxiety” before and during radiotherapy (RT) but did not
investigate the effect of that anxiety on treatment outcomes. “Mask anxiety” does well to
illustrate the experience of many HNC patients. RT is the most common treatment for HNC and
demands the patient lie motionless under an immobilizing mask for up to 15 minutes while
radiation is applied to the target site. RT sessions are thus understandably a source of anxiety for
HNC patients, but it is only one of many worries for this patient population. A diagnosis of HNC
often includes anxiety for the receiving patient, which, depending on coping style, can decrease
treatment adherence(de Oliveira et al., 2017). Anxiety has also been shown to relate to difficulty
with remembering and recalling medical information, contributing to the likelihood of making
underinformed treatment decisions(Kessels, 2003).
From a traditional physician’s perspective, treating a patient’s cancer may seem to be the
most effective way to alleviate accompanying anxiety. However, this approach neglects to
consider an anxious cancer patient’s role in treatment, specifically how his/her anxiety may
affect adherence to treatment and treatment decisions (e.g. whether to begin chemotherapy). One
longitudinal study of 50 Non-Small-Cell Lung Cancer patients found that those who reported

heightened baseline anxiety were significantly more likely to experience treatment delay and/or
reduction(Greer, Pirl, Park, Lynch, & Temel, 2008). Rather, coping style, (the patterns of
behavior one is likely to respond with when confronted with stress) may provide a more accurate
predictor of behavior regarding treatment. An avoidant coping style is characterized by a
diversion of attention from a stress-causing stimulus. In the case of a cancer patient, an avoidant
coping style could mean that he/she does not return to a healthcare facility for follow-up scans or
even for expensive treatments such as RT. As for making appropriate treatment decisions, the
presence of anxiety brings with it the potential to misinterpret the severity of one’s own
condition. As more medical information is presented to a patient, more is forgotten, and the
amount forgotten is positively correlated with anxiety level(Ley, 1979). This could include
details about the disease’s progression or treatment recommendations. For example, in this
situation an anxious individual may conclude that he/she is not ill enough to justify beginning a
chemotherapy regimen, thus potentially making a decision against his/her best interest due in
part to anxiety’s influence on his/her memory for medical information. However, anxiety’s
effects are not limited to treatment adherence and decisions. There are also biological
mechanisms that can be uniquely detrimental to cancer patients.
When an individual experiences significant symptoms of anxiety, he/she is subjected to
consistently high levels of nervousness and worry that together create the psychological
experience of distress. There are numerous physiological consequences of chronic stress such as
immune system suppression(Segerstrom & Miller, 2004) and damaged hippocampal receptors
causing impaired memory(Wingenfeld & Wolf, 2014). Chronic stress has also been linked to the
upregulation of the nuclear factor kappa light-chain-enhancer of activated B cells (NF-κB)
pathway, which mediates the synthesis of proinflammatory molecules throughout the
body(Gupta et al., 2011). This is significant because when dysregulated, this pathway is heavily
implicated in the expression of symptoms of cancer: depression, fatigue, disordered sleep,
anxiety, cognitive impairment, cachexia, anorexia, delirium, and neuropathic pain. One study
found a clear relationship between anxiety and NF-κB activity in breast cancer patients(Antoni et
al., 2012). The experiment involved treating patients with a cognitive-behavioral stress
management intervention and measuring the activity of NF-κB at baseline, 6, and 12-month
follow-ups. It was concluded that the intervention had a significant effect on the NF-κB pathway,
decreasing its activity and therefore decreasing its threat to patient health. This study serves to
highlight two ideas important to this paper: how maladaptive thinking - such as that present in
anxiety - can influence a patient’s physical health via the NF-κB pathway, and how treating that
maladaptive thinking has the potential to ameliorate health problems exacerbated by NF-κB
activation
Upregulation of NF-κB may be stimulated by distress, diet, chemotherapy, infection,
obesity, and addiction with the presence of more than one stimulus creating a cumulative effect
on the pathway(Gupta et al., 2011). That is, an individual who is distressed, obese, and/or
possesses an infection will have a more active NF-κB pathway than an individual who is only
obese (depending on the severity of each condition). Therefore, an individual facing multiple
upregulating stimuli has a greater chance of exhibiting the debilitating symptoms of cancer. In a
patient already diagnosed with cancer, these upregulating stimuli serve to exacerbate their

condition. Note that chemotherapy itself has been shown to dysregulate NF-κB signaling,
meaning that even treatment has the potential to work against the patient to some degree. A
typical cancer patient faces more than one of the above stimuli simultaneously and experiences
more than one symptom of the disease(Cleeland, 2007). In this situation, a predisposition to
anxiety may further magnify the effects of cancer on the body. Therefore, the presence of anxiety
in the cancer patient population is one of physiological concern because it influences the severity
of cancer symptoms.
Beyond contributing to symptoms, NF-κB has been linked to cancer progression with
some calling it the root cause of head and neck squamous cell carcinoma(Monisha et al., 2017).
Research has indicated the activation of NF-κB is a precursor to malignancy and metastasis in
HNC, resulting in poorer overall survival13. Further, NF-κB is a transcription factor for antiapoptotic genes, meaning its persistent activation endorses the survival of cancer cells and allows
them to proliferate in the body(Vander Broek, Snow, Chen, & Van Waes, 2014). As a key
regulator of cell life and death(Colombo, Zambrano, & Agresti, 2018), these findings are
concurrent with the influence of NF-κB signaling on symptomology and represent NF-κB as not
only a factor that influences cancer symptoms, but also one that contributes to the disease itself.
Strong evidence suggests that the NF-κB pathway links the experiences of stress and other
stimuli to the behavior of cancer, and that it represents an obstacle in the treatment of HNC.
While assessment of NF-κB is beyond the scope of the current study, we present these data to
support the notion that symptoms of anxiety may be biologically linked to the progression of
cancer.
As a cancer patient continues along the treatment trajectory, improvement in his/her
condition is measured by means of tumor response to treatment, which is evaluated via change in
tumor size. A tumor’s size is determined by its largest dimension(Shanbhogue, Karnad, &
Prasad, 2010), and its response to treatment is categorized by the change in that dimension
before and after treatment. From there, response to treatment is assessed to be in one of four
categories: complete response (CR) if a tumor appears to be completely eliminated, partial
response (PR) if the tumor’s largest dimension decreases by more than 50%, stable disease (SD)
if the tumor’s largest dimension reduces by less than 50% or increases by less than 25%, or
disease progression (DP) if the tumor’s largest dimension increases by more than 25%. Imaging
technologies such as computerized tomography (CT) and positron emission tomography (PET)
are used to determine response to treatment and are typically employed 3-6 months posttreatment to avoid misinterpretations related to delayed effects of radiation on the body (e.g.,
inflammation)(Hermans, 2004). Although there have been great advances in RT over the
years(Gregoire, Langendijk, & Nuyts, 2015), most HNC patients are diagnosed at an advanced
stage (III or IV) and often face poor prognoses(Cognetti, Weber, & Lai, 2008). Even those who
respond well to treatment remain at risk, as up to 60% of patients diagnosed with HNC develop
recurrent disease, sometimes years after completing treatment. Even soon after completing
treatment, recurrences or treatment failures may occur.
Treatment failure is a useful predictor of overall survival in cancer research. For example,
a study involving patients with non-small-cell lung cancer was able to develop formulas to

determine the effect of treatment response on one-year survival(Shanafelt, Loprinzi, Marks,
Novotny, & Sloan, 2004). An individual whose response to treatment is categorized as SD will
generally have shorter-term survival compared to an individual with an identical condition (type,
stage, and site) categorized as CR or PR, and the category CR does well to represent patients’
disease trajectory as optimistic. While the relationship between optimal treatment response and
overall survival is frequently used in early evaluations assessing the efficacy of new cancer
treatments, treatment failure commonly portends poorer overall survival.
Anxiety’s role in overall survival is less clear mainly because it is understudied(Roth &
Massie, 2007). Nevertheless, biological evidence suggests it plays a role in the
development/escalation of cancer symptoms, therefore having a negative effect on survival.
Further, proinflammatory cytokines produced by the NF-κB pathway--which is upregulated by
factors including stress and anxiety--are implied to cause mood disruption that can worsen the
quality of life of a patient undergoing cancer treatment(Capuron, Ravaud, & Dantzer, 2000; Jehn
et al., 2006; Musselman et al., 2001). In this manner, anxiety has the potential to complicate the
treatment of HNC and increase mortality.
In contrast to the effects of depression on cancer symptomology and trajectory, the
effects of anxiety on the cancer patient population beginning treatment remain
understudied(Howren et al., 2013). This includes the effect of anxiety on treatment response and
overall survival, which should be investigated due to the posited relationship between anxiety
and NF-κB activation, especially since literature on the relationship between anxiety and
treatment response is scant. It is also plausible that treatment response may explain some of the
influence of anxiety level and on overall survival, meaning treatment response likely plays a
mediating role on anxiety and survival. This study aims to address the variables of anxiety,
treatment response, and overall survival via a longitudinal design that measures anxiety
symptoms at the start of treatment, tumor response after completion of treatment 5 months later,
and two-year overall survival. We hypothesize that higher pretreatment anxiety levels in HNC
patients will predict poorer overall two-year survival. We also hypothesize that higher
pretreatment anxiety levels will predict a higher likelihood of subsequent HNC treatment failure.
Finally, we expect that the relationship between higher pretreatment anxiety and poorer two-year
overall survival will be mediated by treatment failure.

Methods
Participants and Procedures
All new patients who presented to the multidisciplinary head and neck cancer clinic at the
James Graham Brown Cancer Center between October, 2013 and March 2017 were reviewed.
This study received approval from our institutional review board with a waiver of informed
consent and an approval number of 13.0053. Participants completed anxiety assessments prior to
or during presentation at the multidisciplinary treatment planning visit. Patients had typically
received notice of their biopsy-proven diagnosis of HNC 1-4 weeks before presentation.

Treatment recommendations generally included surgical extirpation of disease, radiation,
chemotherapy or some combination of the three. Our clinic sees approximately 200 HNC
patients per year, including patients with recurrent or metastatic disease, and patients with
disease at sites other than of the head and neck (e.g., thyroid, skin melanoma). Approximately
400-500 new primary HNC patients were referred to our clinic during the 4.5-year study period.
Patients who returned completed data on anxiety symptoms (approximate N=450) are the focus
of the current analysis.

Measures
Clinical Variables
Patient demographics of age, sex, and alcohol and smoking history were collected from
intake forms. Only patients with HNC as a primary disease were analyzed, excluding those with
recurrent or metastatic disease. Staging followed the guidelines of the American Joint
Commission on Cancer and was determined at the time of presentation using all available
clinical, pathologic, and radiographic data. Tumor location was classified into 1 of 4 categories:
oral, oropharyngeal, hypopharyngeal, or laryngeal. Medical records were reviewed after all
participants had completed treatment, and they provided data on tumor response to treatment and
overall two-year survival. Patients were coded as poorly responsive if their records showed
clinical evidence of disease persistence or tumor progression. Response to treatment was
assessed to be in one of four categories: complete response (CR) if a tumor appeared to be
completely eliminated, partial response (PR) if the tumor’s largest dimension decreased by more
than 50%, stable disease (SD) if the tumor’s largest dimension reduced by less than 50% or
increased by less than 25%, or disease progression (DP) if the tumor’s largest dimension
increased by more than 25%. Overall two-year survival was calculated from the date patients
entered the study, which was also the date that patients met with physicians to plan their
treatment regimen.
Anxiety
Anxiety symptoms were measured at the time of entry using the Generalized Anxiety
Disorders – 7 item scale (GAD–7), which has demonstrated adequate reliability as well as
construct, criterion, and procedural validity(Spitzer, Kroenke, Williams, & Löwe, 2006). It
instructs respondents to indicate on a scale of 0-3 how frequently they have been bothered by 7
different anxiety-related problems (e.g. “worrying too much about different things”) over the
past 2 weeks, with 0 representing “not at all” and 3 representing “nearly every day.” Scores
range from 0-21 and encompass 3 categories of symptom severity. Scores from 5-9 indicate mild
severity, scores from 10-14 indicate moderate severity, and scores above 14 indicate the presence
of severe anxiety symptoms. A score of 10 is generally accepted as a clinical cutoff for
significant symptomology that may require treatment. The GAD-7 has been tested as a screening
tool for Generalized Anxiety Disorder in cancer patients and has been concluded to possess
adequate diagnostic accuracy among this population(Esser et al., 2018). Further, it has previously
been used to study HNC patients, where it was found to have adequate sensitivity and specificity

in determining the presence and severity of distress in its respondents(Polidoro Lima & Osório,
2014).

Statistical Analysis Plan.
Descriptive and summary statistics
Descriptive and summary statistics will be used to characterize clinical and demographic
features of the patient sample. Before analyses, independent variables will be centered at the
mean, and we will confirm all statistical assumptions are met when running tests of hypotheses.
Hypothesis Tests
The relationship between pretreatment anxiety and two-year overall survival will be
examined with a Cox proportional hazards model. The relationship between pretreatment anxiety
and treatment failure will be tested with a logistic regression model. Tests of mediation on the
relationship between pretreatment anxiety and overall survival will then be performed in
accordance with the MacArthur approach, in which centered predictors and their interaction term
are included(Kraemer, Kiernan, Essex, & Kupfer, 2008). To show that B mediates A on C, it
must be shown that A, B, and C happen in that order, that A and B are correlated, and that B
explains all (complete) or part (partial) of the association between A and C. In a linear model,
that means that the main effect of B, the interaction between A and B, or both are statistically
significant. Cox models will be constructed to include pretreatment anxiety symptoms, treatment
failure, and the interaction between the two.
In order to check for possible proxy relationships that may impact our tests of
hypotheses, Spearman rank correlations will assess clinical and demographic indicators,
including cancer stage, site of disease, age at diagnosis, sex, and tobacco history in pack-years.
Those that correlate with both anxiety and survival will be considered possible proxies according
to the MacArthur definition(Kraemer et al., 2008). When this occurs, Cox models will be
constructed to include pretreatment anxiety symptoms, the possible proxy, and the interaction
between the two. All statistical tests will be 2-sided with  set at .05 (SPSS 25; IBM, Armonk,
New York).
Power Analysis
A power analysis was completed based on a comparable study reporting depressive
symptoms as a significant predictor of head and neck cancer survival among 134 patients
experiencing 18 deaths(Zimmaro et al., 2018). The results suggested that our sample of ~450
patients would attain 100% power to detect significant effects in hypothesized relationships.
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